Generalized anxiety disorder affects millions, often trapping sufferers in cycles of fear and isolation that conventional medications barely relieve. At UCSF, neuroscientist Jennifer Mitchell is testing a pharmaceutical form of LSD called MM120, which has shown striking results in reducing symptoms by promoting neuroplasticity and easing rigid thought patterns. In clinical trials, a single dose significantly outperformed standard treatments, offering hope to those who have found little relief elsewhere.

GLP-1 drugs, originally developed for diabetes and obesity, may also curb addictive behaviors by acting on reward circuits in the brain. Early trials show reductions in alcohol intake, opioid seeking, and nicotine use. Though more research is needed, scientists believe these drugs could open a powerful new front in addiction therapy.

Colorado researchers discovered that nearly half of tested cannabis flower products exaggerated their THC levels, while concentrates were mostly accurate. The team’s statewide audit revealed potency inconsistencies that could mislead consumers and affect safe dosing. Beyond THC, the study also found that cannabinoids like CBG and CBGA are underreported. The findings may help shape future regulations and improve consumer trust in the growing cannabis market.

A major collaboration between UC San Diego and 23andMe identified genes that shape cannabis use behaviors. The study linked the CADM2 and GRM3 genes to cannabis use and connected these patterns to more than 100 traits across mental and physical health. Researchers say understanding these genetic influences could help prevent cannabis use disorder and guide future therapies.

Overdose deaths from fentanyl mixed with stimulants have skyrocketed among seniors, increasing 9,000% in just eight years. Once thought to affect mainly the young, the opioid epidemic’s fourth wave now engulfs older adults too. Cocaine and methamphetamine are the leading culprits, and experts warn that multi-drug use makes these overdoses especially lethal. Doctors are urged to educate patients and caregivers on prevention and safer pain management.

Addiction often isn’t about chasing pleasure—it’s about escaping pain. Researchers at Scripps Research have discovered that a tiny brain region called the paraventricular nucleus of the thalamus (PVT) becomes hyperactive when animals learn that alcohol eases the agony of withdrawal. This circuit helps explain why people relapse: their brains learn that alcohol brings relief from stress and anxiety.

Over 40% of fatal crash victims had THC levels far above legal limits, showing cannabis use before driving remains widespread. The rate didn’t drop after legalization, suggesting policy changes haven’t altered risky habits. Experts warn that the lack of public awareness around marijuana’s dangers behind the wheel is putting lives at risk.

Penn researchers found that psilocybin can calm brain circuits tied to pain and mood, easing both physical suffering and emotional distress in animal studies. The compound works in the anterior cingulate cortex, bypassing injury sites and offering a dual benefit for pain and depression. Unlike opioids, psilocybin is non-addictive and may provide relief lasting weeks.

Researchers found that middle-aged adults, especially women, are far more likely to be addicted to ultra-processed foods than older generations. Marketing of diet-focused processed foods in the 1980s may have played a major role. Food addiction was linked to poor health, weight issues, and social isolation, highlighting long-term risks. Experts warn that children today could face even higher addiction rates in the future.

Researchers have created a two-stage acne patch with tiny arrowhead-shaped spikes that deliver healing compounds directly under the skin. Trials showed pimples vanished in seven days, and the technology may expand to treat other conditions.

Nitazenes, a powerful and largely hidden class of synthetic opioids, are quickly becoming a deadly factor in the overdose crisis. Over 20 times stronger than fentanyl, these drugs often go undetected on routine drug tests, making overdoses harder to diagnose and reverse. Cases from Tennessee reveal a disturbing pattern of fatalities, with nitazenes frequently mixed into counterfeit pills alongside fentanyl and methamphetamine.

Some people taking Ozempic, Wegovy, or Mounjaro notice that food suddenly tastes sweeter or saltier, and this subtle shift in flavor perception appears tied to reduced appetite and stronger feelings of fullness. In a study of more than 400 patients, roughly one in five experienced heightened taste sensitivity, and many reported being less hungry and more easily satisfied.

A massive study of over 4 million adults has revealed that cannabis use may nearly quadruple the risk of developing diabetes. Despite some earlier suggestions that cannabis might have metabolic benefits, this large analysis found significantly higher diabetes rates among users, even after adjusting for other health factors.

Scientists at Stellenbosch University have uncovered a rare class of plant compounds, flavoalkaloids, in Cannabis leaves for the first time. Using advanced two-dimensional chromatography and mass spectrometry, they identified 79 phenolic compounds across three strains, 25 of which had never before been reported in Cannabis. The surprising discovery highlights the complexity of the plant and its untapped biomedical potential beyond cannabinoids, opening new doors for research and medicine.

Overactivation of dopamine neurons may directly drive their death, explaining why movement-controlling brain cells degenerate in Parkinson’s. Mice with chronically stimulated neurons showed the same selective damage seen in patients, along with molecular stress responses. Targeting this overactivity could help slow disease progression.

A long-term study following insomnia patients treated with cannabis-based medical products revealed sustained improvements in sleep quality, mood, and pain management over 18 months. Most participants reported better rest and less anxiety or depression, while only a small fraction experienced mild side effects such as fatigue or dry mouth.

A sweeping review of nearly 100 studies has raised concerns about the mental health impacts of high-potency cannabis products. Researchers found strong links to psychosis, schizophrenia, and cannabis use disorder, while results for anxiety and depression were mixed and sometimes contradictory. Although the findings confirm that higher THC concentrations pose risks, the evidence still isn’t clear enough to offer firm clinical guidance, leaving scientists calling for better-designed studies to fill the gaps.

Using cannabis to self-medicate comes with hidden dangers—new research shows these users face higher paranoia and consume more THC. Childhood trauma further amplifies the risks, especially emotional abuse, which strongly predicts paranoia.

THC levels in cannabis have soared in recent years, raising the risk of psychosis—especially in young, frequent users. Studies reveal a strong connection between cannabis-induced psychosis and schizophrenia, making early cessation and treatment essential.

A powerful new synthetic opioid, up to 1000 times stronger than morphine, has emerged in Adelaide’s street drug supply, and researchers are sounding the alarm. Nitazenes, often hidden in heroin or fentanyl, have already caused dozens of deaths in Australia, with most victims unaware they were exposed. Even more concerning, researchers found the sedative xylazine mixed in, echoing deadly drug combinations seen in the U.S.